MONOCLONAL-ANTIBODY ANTI-MPO IS USEFUL IN RECOGNIZING MINIMALLY DIFFERENTIATED ACUTE MYELOID-LEUKEMIA

被引：14

作者：

PRAXEDES, MK ^{[1
]}

DEOLIVEIRA, LZ ^{[1
]}

PEREIRA, WD ^{[1
]}

QUINTANA, IZ ^{[1
]}

TABAK, DG ^{[1
]}

DEOLIVEIRA, MSP ^{[1
]}

机构：

[1] INST NACL CANC,CEMO,CELL MARKERS LAB,PRACA CRUZ VERMELHA 23,RIO JANEIRO,BRAZIL

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 12卷 / 3-4期

关键词：

MONOCLONAL ANTIBODY; ANTI-MPO; MINIMALLY DIFFERENTIATED LEUKEMIA;

D O I：

10.3109/10428199409059594

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The enzyme myeloperoxidase (MPO) is the most specific marker of myeloid lineage. The recognition of acute myeloid leukaemia (AML) with minimally differentiation (AML-M0) is established with methods that include myeloid markers CD13/CD33 and detection of MPO in blast cells by immunological techniques or electron microscopy Cytochemistry (EM). We have analysed the presence of MPO in leukaemic blast cells by conventional cytochemistry and immunological methods using a monoclonal antibody anti-MPO (CLB-MPO1) in 121 cases of acute leukaemia. The aim of the study was to investigate the sensitivity of this McAb to identify AML-MO, as CD13/CD33 can be expressed in some cases of acute lymphoblastic leukaemia (ALL) and EM cytochemistry is not always available in many laboratories. Anti-MPO was positive in all cases of AML (MI-M5) which were positive by Sudan Black B reaction in similar or higher percentage ratio for each case, although in some of them did not label with CD13/CD33 tested by IF and IPc techniques. Based on the anti-MPO positivity, 5 out of 10 cases called undifferentiated leukaemia (AUL), were reclassified as AML-MO, though 4 cases were CD13/CD33 negative. Furthermore, after analysing the anti-MPO expression among 32 cases of ALL, we had to reclassify four of them as acute biphenotypic leukaemia. We conclude that anti-MPO is a very sensitive and reliable tool in AML diagnosis and has an important role in distinguishing minimally differentiated AML and biphenotypic acute leukaemia from AUL and ALL.

引用

页码：233 / 239

页数：7

共 25 条

[1]

Hayhoe F.G.J., Cawley J.C., Acute leukaemia: Cellular morphology, cytochemistry and fine structure, Clin. Hematol., 1, pp. 49-53, (1972)

[2]

Baiton D.F., Ullyot J.L., Farguhar M.G., The development of neutrophilic polymorphonuclear leukocytes in human bone marrow: origin and content of azurophil and specific granules, J. Exp. Med., 134, pp. 907-934, (1971)

[3]

Bennett J., Catovsky D., Daniel M.T., Flandrin G., Gal-Ton D.A.G., Gralnick H.R., Sultan C., Proposed revised criteria for the classification of acute myeloid leukaemia, Ann. Int. Med., 103, pp. 626-629, (1985)

[4]

Matures E., Pombo de Oliveira M.S., Foroni L., Morilla R., Catovsky D., The role of ultrastructural cytochemistry and monoclonal antibodies in clarifying the nature of undifferentiated cells in acute leukaemia, Brit. J. Haematol., 69, pp. 205-211, (1988)

[5]

Pombo de Oliveira M.S., Matutes E., Rani S., Morilla R., Catovsky D., Early expression of MCS2 (CD13) in the cytoplasm of blast cells from acute myeloid leukaemia, Acta. Haematol., 80, pp. 61-64, (1988)

[6]

Lee E.J., Polliack A., Leavitt R.D., Testa R.J., Schiffer C.A., Minimally differentiated acute non-lymphocytic leukemia: a distinct entity, Blood, 70, pp. 1400-1406, (1987)

[7]

Bennett J., Catovsky D., Daniel M.T., Flandrin G., Gal-Ton D.A.G., Gralnick H.R., Sultan C., Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO), Brit. J. Haematol., 78, pp. 325-329, (1991)

[8]

Sobol R.E., Mick M.S., Royston I., Davey F.R., Ellison R.R., Newman R., Cuttner J., Griffin J.D., Collins H., Nelson D.A., Bloomfield C.D., Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukaemia, N. Engl. J. Med., 316, pp. 1111-1117, (1987)

[9]

Wiersma S.R., Ortega J., Sobel E., Weinberg K.I., Clinical importance of myeloid antigen expression in acute lymphoblastic leukemia of childhood, N. Engl. J. Med., 324, pp. 800-808, (1991)

[10]

Urbano-Ispizua A., Matutes E., Villamor N., Ribera J.M., Feliu E., Monserrat E., Grenena A., Vives-Corrons J.L., Rozman C., Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukaemia, Brit. J. Haematol., 75, pp. 202-207, (1990)

← 1 2 3 →